Literature DB >> 25944067

[Kernicterus is preventable but still occurs].

Sara Bousema1, Paul Govaert, Jeroen Dudink, Eric A P Steegers, Irwin K M Reiss, Rogier C J de Jonge.   

Abstract

Kernicterus is a severe neurological condition, caused by bilirubin-induced damage in the basal ganglia. The neurological outcome is often poor. In the past decades there seems to have been an increase in the number of reported cases of kernicterus. In order to raise awareness of this condition, we present two patients with kernicterus caused by different pathophysiological mechanisms. In both cases we make suggestions for the improvement of the medical care process. The first patient is a 7-day-old girl with kernicterus due to haemolysis caused by G6PD deficiency. Patient B is a 3-day-old boy with hyperbilirubinaemia based on 0/B blood group incompatibility. Kernicterus resulted in significant disabilities in these children. A proper diagnostic approach and precise treatment of hyperbilirubinaemia are essential to prevent major neurological damage. Awareness of this condition, education of health care professionals and changes in in- and outpatient care are needed to achieve this goal.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25944067

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  Screening and treatment to reduce severe hyperbilirubinaemia in infants in primary care (STARSHIP): a factorial stepped-wedge cluster randomised controlled trial protocol.

Authors:  Berthe A M van der Geest; Johanna P de Graaf; Loes C M Bertens; Marten J Poley; Erwin Ista; René F Kornelisse; Irwin K M Reiss; Eric A P Steegers; Jasper V Been
Journal:  BMJ Open       Date:  2019-04-20       Impact factor: 2.692

2.  Assessing knowledge and skills of maternity care professionals regarding neonatal hyperbilirubinaemia: a nationwide survey.

Authors:  Berthe A M van der Geest; Imke M Theeuwen; Irwin K M Reiss; Eric A P Steegers; Jasper V Been
Journal:  BMC Pregnancy Childbirth       Date:  2021-01-19       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.